Chemomab Therapeutics Ltd... (CMMB)
Chemomab Therapeutics Ltd. (CMMB) Stock Price, Analysis & Data
| Bid | n/a |
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.45M |
| Beta | 0.66 |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Forward PE | -64 |
| P/B (ttm) | 1.29 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 20, 2025 |
| Ask | n/a |
| Volume | NaN |
| Avg. Volume (20D) | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a - n/a |
| 52-Week Range | n/a - n/a |
| Analyst | n/a |
| Price Target | 5 (NaN%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CMMB
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as ...
Financial Performance
In 2025, Chemomab Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -8.99M, a decrease of -35.5%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for CMMB stock is "null". The 12-month stock price forecast is 5, which is downside of NaN% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
